Macrophage activation syndrome vs. Hemophagocytic lymphohistiocytosis ...
2018年8月31日 · Macrophage activation syndrome (MAS) is a life-threatening complication of rheumatic diseases (i.e SLE, Juvenile idiopathic arthritis, Adult onset Still’s disease). It …
五大方面，一文讲清风湿性疾病相关噬血细胞综合征诊疗规范
2022年5月24日 · 巨噬细胞活化综合征（macrophage activation syndrome，MAS）是HLH的一种类型，特指继发于风湿性疾病的HLH，亦被称为“反应性噬血细胞综合征”。 目前已发现超过 …
Hemophagocytic lymphohistiocytosis and macrophage activation …
2024年4月16日 · Hemophagocytic lymphohistiocytosis (HLH) is a rare genetic hyperinflammatory syndrome that occurs early in life. Macrophage activation syndrome (MAS) usually refers to a …
Macrophage Activation Syndrome Versus Hemophagocytic ...
Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are two overlapping, potentially fatal syndromes classified by disorganization and malfunction of the …
The 2022 EULAR/ACR points to consider at the early stages of …
Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes characterised by fever, elevated …
UpToDate
Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. It most frequently affects infants from birth to 18 months of age, …
Diagnosis and Management of Secondary HLH/MAS Following …
Introduction: Secondary haemophagocytic lymphohistiocytosis (sHLH) or Macrophage Activation Syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can occur in patients …
【肿瘤诊疗】HLA分型 - 知乎 - 知乎专栏
主要组织相容性复合体 （MHC）是一组编码细胞表面蛋白，用于细胞间识别和 抗原识别和抗原呈递，呈现高度多态性，在人类称为 HLA复合体 （人类白细胞抗原）。 HLA复合体定位第6号 …
The genetics of macrophage activation syndrome | Genes
2020年4月15日 · Macrophage activation syndrome (MAS), or secondary hemophagocytic lymphohistiocytosis (HLH), is a cytokine storm syndrome associated with multi-organ system …
T-ing up the storm: pathogenic cycling lymphocytes in the biology …
2 天之前 · The expansion of cycling lymphocytes correlates with disease activity and helps to distinguish HLH / MAS from clinical mimics. We demonstrate an approach to quantify CD38 + …